Figure 1
Figure 1. Human platelets incorporate into NOD/SCID mouse thrombi. (A-F) Washed human platelets (5% of the total platelet population) were mixed with anticoagulated whole blood from NOD/SCID mice, incubated without (A) or with moAbs 24B3 (B), 6B4 (C), 16N7C2 (D), or 6B4 + 16N7C2 (E; 10 μg/mL each) and perfused at 1500 seconds−1 over coverslips coated with collagen (200 μg/mL). Murine and human platelets were labeled with anti-mouse CD42c-Alexa 488 and anti-human CD61-PE, respectively. (F) Surface covered by human platelets, expressed as the percentage of the total surface observed, was calculated at the indicated perfusion times. Data represent mean ± SEM (n = 3 for each group). Statistical analysis was performed using unpaired Student t test. *P < .05; **.001 < P < .05; ***P < .001. Control (■), 24B3 (), 6B4 (□), 16N7C2 (▩), 6B4 + 16N7C2 (▨). Mouse platelets in control PB represented 20.8% ± 2.5% of the total surface coverage (mean ± SEM of 9 fields, n = 3), and was not significantly different from moAb-treated PB (> 5 fields, n = 3).

Human platelets incorporate into NOD/SCID mouse thrombi. (A-F) Washed human platelets (5% of the total platelet population) were mixed with anticoagulated whole blood from NOD/SCID mice, incubated without (A) or with moAbs 24B3 (B), 6B4 (C), 16N7C2 (D), or 6B4 + 16N7C2 (E; 10 μg/mL each) and perfused at 1500 seconds−1 over coverslips coated with collagen (200 μg/mL). Murine and human platelets were labeled with anti-mouse CD42c-Alexa 488 and anti-human CD61-PE, respectively. (F) Surface covered by human platelets, expressed as the percentage of the total surface observed, was calculated at the indicated perfusion times. Data represent mean ± SEM (n = 3 for each group). Statistical analysis was performed using unpaired Student t test. *P < .05; **.001 < P < .05; ***P < .001. Control (■), 24B3 (), 6B4 (□), 16N7C2 (▩), 6B4 + 16N7C2 (▨). Mouse platelets in control PB represented 20.8% ± 2.5% of the total surface coverage (mean ± SEM of 9 fields, n = 3), and was not significantly different from moAb-treated PB (> 5 fields, n = 3).

Close Modal

or Create an Account

Close Modal
Close Modal